/

PRME

Prime Medicine, Inc.Open

3.35−0.26 −7.34%USD

NasdaqGM · as of Oct 13, 12:41 ET · 15m delay

Open

3.61

Prev close

3.61

Day range

3.273.61

52-week range

2.676.65

Volume

1.86M0.55×

Mkt cap

606.71M

P/E ttm

—

Fwd P/E

-3.77

EPS ttm

-1.07

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−49.70%

Price Chart

Yahoo Finance · delayed

PRMEOct 13, 2026O 3.61H 3.61L 3.27C 3.35−0.26 (−7.34%)Vol 1.86M

SMA 503.31
SMA 2003.48

1Y change −41.11% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PRME Prime Medicine, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.43%
1 month: +6.87%
3 months: −3.60%
6 months: −9.59%
Year to date: −3.60%
1 year: −40.80%

Valuation & ownership

Market cap: 606.71M
Enterprise value: 659.64M
P/E (ttm): —
Forward P/E: -3.77
PEG ratio: —
Price / book: 14.87
Price / sales (ttm): 148.96
EV / EBITDA: -3.49
EPS (ttm): -1.07
EPS (forward): -0.8880
Beta (5y monthly): 2.38
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 181.38M
Float: 112.25M
Short % of float: 22.64%
Short ratio (days): 9.99
Held by insiders: 20.30%
Held by institutions: 70.99%
Avg volume (3m): 3.38M
50-day average: 3.30
200-day average: 3.48
52-week change: −40.80%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 49.9
vs 50-day SMA: +1.10%
vs 200-day SMA: −3.81%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 10.02%
Realised vol (20d, ann.): 114.9%
From 52-week high: −49.70%
From 52-week low: +25.28%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

7.11

+112.66% implied

Low 4.25Median 7.00High 11.00

Recommendation trend

Now11 / 3 / 0
1m ago / 3 /

DES

About Prime Medicine, Inc.

Yahoo Finance profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 146
Headquarters: Cambridge, MA, United States
Website: primemedicine.com
Officers: Mr. Jeffrey D. Marrazzo M.B.A., M.P.A.

SEAS

Seasonality · PRME

2022–2026 · monthly returns

Strongest month Jun +31.81%Weakest month Mar −21.69%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	9.8	21.3	-24.7	1.9	0.1	3.9	-20.9	22.9	-14.9	9.5			−3.6%
2025	-4.1	-10.0	-21.0	-13.1	-31.8	109.3	51.4	-13.4	71.0	-10.8	-22.7	-9.2	+18.8%
2024	-28.3	35.9	-18.9	-29.7	31.7	-20.7	9.1	-23.7	-9.6	0.3	-15.2	-11.2	−67.0%
2023	-5.4	-6.5	-25.1	12.0	-0.4	6.8	2.9	-12.1	-27.9	-32.0	11.9	22.0	−52.3%
2022											-8.7	8.1	−1.3%

INSD

Insider Activity · PRME

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 31, 2025	Nelsen Robert TaylorDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 3.30 per share.	3.03M	$10.00M
Jul 31, 2025	Arch Venture Partners X LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 3.30 per share.	3.03M	$10.00M
Jul 31, 2025	Gv 2021 Gp, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 3.30 per share.	1.50M	$4.95M
Jun 29, 2025	Liu David RBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.52 per share.	21K	$52.83K
Jun 22, 2025	Liu David RBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.16 per share.	21K	$45.40K
Jun 15, 2025	Liu David RBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.49 per share.	21K	$31.20K
Jun 10, 2025	Liu David RBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.60 per share.	21K	$33.59K
May 20, 2025	Reine AllanChief Executive Officer	Purchase at price 1.18 per share.	125K	$147.15K
May 20, 2025	Lee Ann LouiseOfficer	Purchase at price 1.13 per share.	100K	$113.00K
May 19, 2025	Brudnick RichardOfficer	Purchase at price 1.19 per share.	20K	$23.79K

13F

Investors Holding PRME

latest 13F filings of 29 followed managers

Investors holding PRME
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$30.8M	0.20%	8.35M	+34%	Q2 2026
Renaissance Technologies	$433.3K	0.00%	117.41K	−84%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PRME

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PRME

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Prime Medicine, Inc.

Seasonality · PRME

Insider Activity · PRME

Congress Trades · PRME

Investors Holding PRME

Investors Holding PRME

Congress Trades · PRME

Insider Activity · PRME

Seasonality · PRME

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Prime Medicine, Inc.

Financial Snapshot

Earnings & Dividends

News